---
schema_version: "secwatch.filing_event.v1"
accession: "0001731122-24-001548"
form_type: "8-K"
ticker: null
cik: "0001708331"
company_name: "Virpax Pharmaceuticals, Inc."
filed_at: "2024-10-07T23:59:59+00:00"
generated_at: "2026-05-30T19:19:02.383770+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Virpax receives Nasdaq deficiency notice; CEO and CFO resign citing policy disagreements

## Summary
- Nasdaq notified Virpax that its bid price was below $1.00 for 30 consecutive days; compliance deadline April 2, 2025.
- CEO Gerald Bruce and CFO Vinay Shah resigned Oct 5 effective immediately, citing disagreements with Board's execution of policies.
- Board appointed director Jatinder Dhaliwal as CEO effective Oct 6; Katharyn Field joins audit committee replacing Dhaliwal.
- Company may consider a reverse stock split to regain compliance, but no assurance of success.

## SEC filing metadata
- accession: 0001731122-24-001548
- form_type: 8-K
- cik: 0001708331
- company_name: Virpax Pharmaceuticals, Inc.
- filed_at: 2024-10-07T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01, 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708331/000173112224001548/0001731122-24-001548-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708331/000173112224001548/e6009_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001731122-24-001548
- JSON: https://secwatch.observer/filing/0001731122-24-001548.json
- Plain text: https://secwatch.observer/filing/0001731122-24-001548.txt

## Key facts
- Executive change
  Jatinder Dhaliwal was appointed as Chief Executive Officer at Virpax Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Chief Executive Officer
  source text: On October 6, 2024, the Board appointed Jatinder Dhaliwal, a member of the Board, to serve as Chief Executive Officer of the Company, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708331/000173112224001548/0001731122-24-001548-index.htm
- Executive change
  Vinay Shah resigned as Chief Financial Officer at Virpax Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: On October 5, 2024, Gerald Bruce, as Chief Executive Officer and member of the Board of Directors (the “Board”), and Vinay Shah, as Chief Financial Officer, notified the Company of their intention to resign for their respective positions, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708331/000173112224001548/0001731122-24-001548-index.htm
- Executive change
  Gerald Bruce resigned as Chief Executive Officer at Virpax Pharmaceuticals, Inc..
  - Action: resigned
  - Role: Chief Executive Officer
  source text: On October 5, 2024, Gerald Bruce, as Chief Executive Officer and member of the Board of Directors (the “Board”), and Vinay Shah, as Chief Financial Officer, notified the Company of their intention to resign for their respective positions, effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708331/000173112224001548/0001731122-24-001548-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.